Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arecor Therapeutics (FRA:6UI) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Arecor Therapeutics Days Sales Outstanding Related Terms
Arecor Therapeutics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Arecor Therapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6UI vs VRTX, REGN, MRNA: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Arecor Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arecor Therapeutics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Arecor Therapeutics's Days Sales Outstanding falls into.
Arecor Therapeutics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arecor Therapeutics (FRA:6UI) has a Days Sales Outstanding of 0.00 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Arecor Therapeutics and its competitors. Over the past decade, Arecor Therapeutics' Days Sales Outstanding has ranged from 78.46 to 533.06. According to the industry distribution chart, Arecor Therapeutics ranks #778 out of 841 companies in the Biotechnology industry, placing it in the top 92.5%.
Is Arecor Therapeutics' Days Sales Outstanding too high?
Arecor Therapeutics' current Days Sales Outstanding is 0.00. Over the past 10 years, this metric has ranged from a low of 78.46 to a high of 533.06. Based on the distribution chart, Arecor Therapeutics ranks #778 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arecor Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Arecor Therapeutics' Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arecor Therapeutics ranks #778 out of 841 companies for Days Sales Outstanding. This places Arecor Therapeutics in the lower half of its industry. The industry median Days Sales Outstanding is 68.94. Historically, Arecor Therapeutics' own Days Sales Outstanding has ranged from 78.46 to 533.06 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Arecor Therapeutics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arecor Therapeutics's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arecor Therapeutics stock overvalued right now?
Arecor Therapeutics (FRA:6UI) has a current Days Sales Outstanding of 0.00. The stock's GF Value™ is €0.41, compared to a current price of €0.79 — trading 91.5% above its estimated fair value. The current Days Sales Outstanding is 0.00. Arecor Therapeutics' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Arecor Therapeutics (FRA:6UI), the current Days Sales Outstanding is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arecor Therapeutics (FRA:6UI) Overvalued in 2026?
Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued.
The current stock price of €0.79 is trading 91.5% above its estimated GF Value™ of €0.41.
Key valuation signals for FRA:6UI:
Days Sales Outstanding: 0.00
GF Value™: €0.41 vs. price of €0.79 (91.5% above fair value)
No single metric tells the full story. See the FRA:6UI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
26GF Score
Get the complete analysis for FRA:6UI
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6UI has been successfully added to your 
